Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Fox Chase Cancer Center
University of Cincinnati
Novartis
Washington University School of Medicine
Masonic Cancer Center, University of Minnesota
Yonsei University
University of Michigan Rogel Cancer Center
Vanderbilt-Ingram Cancer Center
University of Alabama at Birmingham
OHSU Knight Cancer Institute
GlaxoSmithKline
M.D. Anderson Cancer Center
University of Utah
Vanderbilt-Ingram Cancer Center
M.D. Anderson Cancer Center
University of California, San Francisco
University of California, San Francisco
Abbott